# Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Study · id `cardio:ct-nct06327815` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06327815](<https://clinicaltrials.gov/study/NCT06327815>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06327815

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 633 participants.

## Technical summary

Registry record NCT06327815. Randomized; no masking; primary purpose treatment. Start 2024-03-15 (actual); primary completion 2025-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 633 participants (enrolled count; ClinicalTrials.gov record NCT06327815, source copy `cardio:ctgov-nct06327815-2025-10-31`, retrieved 2026-10-26)
- Started: 2024-03-15 (actual) (ClinicalTrials.gov record NCT06327815, source copy `cardio:ctgov-nct06327815-2025-10-31`, retrieved 2026-10-26)
- Primary completion: 2025-06-30 (actual) (ClinicalTrials.gov record NCT06327815, source copy `cardio:ctgov-nct06327815-2025-10-31`, retrieved 2026-10-26)
- Completion: 2025-06-30 (actual) (ClinicalTrials.gov record NCT06327815, source copy `cardio:ctgov-nct06327815-2025-10-31`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06327815, source copy `cardio:ctgov-nct06327815-2025-10-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06327815-2025-10-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets
- Intervention (Drug): Dapagliflozin tablets and Metformin HCl extended-release tablets
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 83919b89fba902b5847b4ab8ea6bcb330cfdc394327e99dd0e52d814aea6b217
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
